Search

Author/Creator Meng, Robin

1. A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma. Issue 1 (31st October 2022)

Authors:
Carlo‐Stella, Carmelo; Zinzani, Pier Luigi; Sureda, Anna; Araújo, Luis; Casasnovas, Olivier; Carpio, Cecilia; Yeh, Su‐Peng; Bouabdallah, Krimo; Cartron, Guillaume; Kim, Won Seog; Cordoba, Raul; Koh, Youngil; Re, Alessandro; Alves, Daniela; Chamuleau, Martine; Le Gouill, Steven; López‐Guillermo, A...
Journal:
Hematological oncology
Issue:
Volume 41:Issue 1(2023)
Page Start:
108
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Plerixafor and granulocyte‐colony‐stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non−Hodgkin's lymphoma: a randomized Phase 3 study. Issue 1 (13th December 2017)

Authors:
Zhu, Jun; Huang, Huiqiang; Chen, Huan; Zhang, Xi; Li, Zengjun; Wu, Depei; Zhou, Daobin; Song, Yongping; Hu, Yu; Liang, Yingmin; Ren, Hanyun; Huang, He; Li, Nainong; Chen, Hu; Hu, Jiong; Li, Jianyong; Meng, Robin; Wu, Junlong; Yu, Dong; Huang, Xiaojun
Journal:
Transfusion
Issue:
Volume 58:Issue 1(2018)
Page Start:
81
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. Issue 1 (20th January 2022)

Authors:
Zucali, Paolo Andrea; Lin, Chia-Chi; Carthon, Bradley C; Bauer, Todd M; Tucci, Marcello; Italiano, Antoine; Iacovelli, Roberto; Su, Wu-Chou; Massard, Christophe; Saleh, Mansoor; Daniele, Gennaro; Greystoke, Alastair; Gutierrez, Martin; Pant, Shubham; Shen, Ying-Chun; Perrino, Matteo; Meng, Robin;...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 1(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗